OS Therapies (NYSEAMERICAN:OSTX) Issues Earnings Results

OS Therapies (NYSEAMERICAN:OSTX) issued its earnings results on Tuesday. The company reported ($0.41) earnings per share for the quarter, FiscalAI reports.

OS Therapies Stock Down 3.5%

OSTX opened at $1.36 on Thursday. OS Therapies has a 12-month low of $1.12 and a 12-month high of $2.57. The business has a 50 day moving average of $1.40 and a 200-day moving average of $1.65. The stock has a market cap of $47.89 million, a price-to-earnings ratio of -1.37 and a beta of -2.95.

Institutional Investors Weigh In On OS Therapies

Large investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new stake in OS Therapies during the 3rd quarter valued at $183,000. Two Sigma Investments LP acquired a new position in shares of OS Therapies in the third quarter valued at $169,000. Geode Capital Management LLC raised its position in shares of OS Therapies by 31.1% in the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock valued at $344,000 after purchasing an additional 58,350 shares during the period. Virtu Financial LLC raised its position in shares of OS Therapies by 252.0% in the third quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after purchasing an additional 54,269 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of OS Therapies during the 2nd quarter worth about $63,000.

Analyst Ratings Changes

Separately, D. Boral Capital reissued a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.50.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.